
    
      OUTLINE: This is a multi-center study.

        -  Patients will be randomly assigned by study number to receive 4mg of zoledronic acid
           every three months or to be observed.

      Performance status: ECOG performance status 0-3 (KPS 30 - 100)

      Life expectancy: 12 months

      Hematopoietic:

        -  Hb >10 g/dl within 14 days prior to registration

      Hepatic:

        -  Not specified

      Renal:

        -  Serum creatinine < 2 mg/dl within 14 days prior to registration

      Cardiovascular:

        -  Not specified

      Pulmonary:

        -  Not specified
    
  